Novel MRI Approaches To Map Focal Cortical Dysplasia In Focal Epilepsy
Funder
National Health and Medical Research Council
Funding Amount
$465,489.00
Summary
Focal cortical dysplasia (FCD) is a common cause of focal epilepsy that is resistant to medication. When it can be identified clearly, surgical removal can cure the epilepsy but better methods of detecting and mapping FCD are required because standard imaging techniques are negative in 30% of patients. In this project, we plan to develop new MRI methods to diagnose FCD, thereby creating a new MRI-based diagnostic tool for patients with focal epilepsy who are potential surgical candidates.
Development Of A PET Detection System Prototype With Depth Of Interaction Capability
Funder
National Health and Medical Research Council
Funding Amount
$360,906.00
Summary
This development project invovles the development of a slim-line Positron Emission Tomogrphy (PET) detection sub-module, the crucial component of PET scanners, that is small and extremely flexible. It is planned to utilize this module in the design of customized new commercial PET scanners ideal for diagnosing human brain and breast disorders. The development will proceed in collaboration with Insight Oceania-ADAC, Sydney. Insight Oceania-ADAC are very excited by the potential applications and f ....This development project invovles the development of a slim-line Positron Emission Tomogrphy (PET) detection sub-module, the crucial component of PET scanners, that is small and extremely flexible. It is planned to utilize this module in the design of customized new commercial PET scanners ideal for diagnosing human brain and breast disorders. The development will proceed in collaboration with Insight Oceania-ADAC, Sydney. Insight Oceania-ADAC are very excited by the potential applications and future markets (Australia and overseas) of the newly developing PET detection sub-modules for dedicated PET scanners. Positron Emission Tomography (PET) is a functional imaging tool, which is able to quantify physiological and biochemical processes in vivo, using short-lived cyclotron-produced radiotracers. PET is emerging as an extremely important diagnostic procedure used in the early detection of cancers, neurological diseases and as an aid in treatment monitoring and drug development. The unique advantage of PET over anatomical imaging techniques, such as X-ray CT and MRI, arises from its ability to measure changes in tumour biology, at the molecular level, prior to anatomical changes in involved tissues, using trace amounts of a radiolabelled compound (radiotracer). The full potential of PET however, is not being completely utilized due to constraints within the current designs of PET scanners. When used to its full potential PET, in principle, would be an excellent diagnostic and treatment monitoring tool for breast cancer, brain tumours and other neurological conditions such as epilepsy, Alzheimer's, Parkinson's disease, post stress disorder, dementia, and depression. Lack of flexibility in current PET scanner designs to date has meant that no commercial human brain or breast imaging scanners exist. Pilot project data proved the feasibility of our new flexible PET detection module design.Read moreRead less
The Effects Of Inherent Inaccuracies In DXA In Vivo BMD Measurements On Osteopenic/Osteoporotic Diagnostics/Prognositics
Funder
National Health and Medical Research Council
Funding Amount
$411,980.00
Summary
Osteoporosis (porous bone) and consequent associated bone fractures of mainly post-menopausal women and the elderly of both genders constitutes a significant, widespread and rapidly growing public health problem. It is already a major health-cost burden in Australia and worldwide and is set to increase dramatically over the next few decades as the proportion of the population at or above the osteoporosis-prone age increases sharply. Current diagnostic evaluations of osteoporosis, bone mineral st ....Osteoporosis (porous bone) and consequent associated bone fractures of mainly post-menopausal women and the elderly of both genders constitutes a significant, widespread and rapidly growing public health problem. It is already a major health-cost burden in Australia and worldwide and is set to increase dramatically over the next few decades as the proportion of the population at or above the osteoporosis-prone age increases sharply. Current diagnostic evaluations of osteoporosis, bone mineral status of the skeleton, mechanical integrity of bone, and bone fracture risk are mainly based on X-ray absorption measurements of a given individual's bone mineral density (BMD) using Dual-energy X-ray Absorptiometric (DXA) bone densitometer instrumentation. New drugs to retard, ameliorate, or reverse the low bone mineral density condition of osteoporosis are now becoming available, but cannot be prescribed unless sufficiently low BMD is demonstrated for a given patient. The efficacy of these drugs is usually held to be greatest at the earliest stage of osteoporosis (osteopenia) and their effectiveness evaluated on the basis of DXA-measured bone mineral density. The Chief Investigator of this project has already shown by published quantitative analysis and simulation studies that such BMD measurements are inherently inaccurate; that errors of 20% and greater can readily pertain, particularly for those patients at the early stages of osteoporosis and those at or above the osteoporosis-prone age -- the very individuals for whom bone mineral density values are often of paramount interest and concern. These systematic DXA inaccuracies can be large enough to either mask the presence of osteoporosis or lead to false diagnoses and patient monitoring results. The present project, for the first time anywhere, is desiged to quantitatively establish the extent of these inaccuracies using actual DXA densitometers utilizing sophisitcated and precise methods.Read moreRead less